VCTX 212
Alternative Names: VCTX-212Latest Information Update: 01 Mar 2023
At a glance
- Originator CRISPR Therapeutics; ViaCyte Inc
- Class Gene therapies; Pluripotent stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 22 Jul 2022 Early research in Type 1 diabetes mellitus in Switzerland (Parenteral), prior to July 202 (CRISPR Therapeutics pipeline, July 2022)
- 22 Jul 2022 Early research in Type 1 diabetes mellitus in USA (Parenteral), prior to July 202 (CRISPR Therapeutics pipeline, July 2022)
- 22 Jul 2022 Early research in Type 2 diabetes mellitus in Switzerland (Parenteral), prior to July 202 (CRISPR Therapeutics pipeline, July 2022)